Mabpharm Limited (2181) AI Stock Analysis

• Market Cap: HK$2.06B
• Dividend Yield: N/A
• Average Volume (3M): 139.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: 190.48%
• EPS Growth: 40.11%
• Country: HK
• Employees: 315
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 4,124,080,000
• 10 Day Avg. Volume: 42,600
• 30 Day Avg. Volume: 139,600
• PEG Ratio: -0.23
• Price to Book (P/B): 13.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -21.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: HK$0.50 ▲(0.00%Upside)

The low overall stock score is primarily due to financial instability and negative cash flows, which highlight significant financial risks. Technical analysis provides a neutral outlook with no strong momentum indicators, while valuation metrics reflect ongoing losses.

Mabpharm Limited Business Overview & Revenue Model

Company Description

Mabpharm Limited (2181) is a biopharmaceutical company focused on the research, development, and commercialization of monoclonal antibody drugs. The company operates primarily in the biotechnology sector, specializing in the treatment of autoimmune diseases, cancer, and infectious diseases. Mabpharm Limited is dedicated to providing innovative therapeutic solutions to enhance patient care and improve health outcomes.

How the Company Makes Money

Mabpharm Limited generates revenue through the development and commercialization of its proprietary monoclonal antibody drugs. The company's key revenue streams include sales of its therapeutic products to healthcare providers and institutions, as well as collaborations and licensing agreements with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties based on product sales. Additionally, Mabpharm Limited may receive government grants and financial support for research and development activities, contributing to its overall earnings.

Mabpharm Limited Financial Statement Overview

Summary

Mabpharm Limited is experiencing rapid revenue growth but continues to face profitability and financial stability challenges. High leverage and negative cash flows suggest a significant reliance on external financing and potential financial risks. The company needs to focus on improving operational efficiency and profitability for sustainable growth.

Income Statement

Mabpharm Limited has shown significant revenue growth of 196.24% from the previous year, indicating strong top-line expansion. However, the company remains unprofitable with a negative net profit margin of -49.55% and a negative EBIT margin of -46.34%. Despite the improvement in revenue, consistent losses over the years indicate challenges in achieving profitability.

Balance Sheet

The company exhibits a high debt-to-equity ratio of 3.50, reflecting substantial leverage and potential financial risk. The return on equity is negative at -143.89%, aligning with ongoing net losses. The equity ratio of 8.75% suggests limited equity as a proportion of total assets, further emphasizing financial instability.

Cash Flow

Mabpharm Limited's cash flow statements reveal challenges with cash generation, as evidenced by the absence of free cash flow and operating cash flow for the current period. Historical free cash flow has been negative, indicating ongoing cash management issues. The inability to generate positive operating cash flow relative to net income further highlights the need for operational improvements.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
258.23M	87.16M	55.92M	82.88M	0.00
	Gross Profit
219.39M	75.24M	40.54M	66.11M	0.00
	EBIT
-119.67M	-201.98M	-203.83M	-289.27M	-180.69M
	EBITDA
-67.81M	-139.08M	-152.08M	-245.46M	-169.93M
	Net Income Common Stockholders
-127.95M	-209.36M	-210.62M	-294.22M	-188.57M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
89.34M	173.34M	48.61M	81.56M	484.85M
	Total Assets
1.02B	1.03B	917.52M	899.90M	1.16B
	Total Debt
293.09M	260.07M	126.34M	45.69M	40.35M
	Net Debt
203.75M	86.73M	92.77M	-35.87M	-444.50M
	Total Liabilities
927.28M	829.92M	516.58M	297.92M	281.55M
	Stockholders Equity
88.93M	205.06M	400.94M	601.98M	881.49M
Cash Flow		Free Cash Flow
-63.58M	38.35M	-182.01M	-348.14M	-344.47M
	Operating Cash Flow
-4.10M	57.39M	-56.88M	-199.47M	-147.23M
	Investing Cash Flow
-98.20M	-3.50M	-104.95M	-179.42M	156.00M
	Financing Cash Flow
18.28M	85.60M	112.26M	-17.78M	-80.48M

Mabpharm Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2181, the sentiment is Positive. The current price of 0.5 is above the 20-day moving average (MA) of 0.46, above the 50-day MA of 0.48, and above the 200-day MA of 0.37, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.72 is Neutral, neither overbought nor oversold. The STOCH value of 48.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2181.

Mabpharm Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2269	74 Outperform	$102.53B	28.08	8.17%	―	7.52%	-1.92%
9992	70 Neutral	€326.73B	95.12	33.41%	0.38%	103.44%	186.51%
1548	62 Neutral	$28.33B	0.97	-6.09%	―	41.41%	7.26%
1873	59 Neutral	HK$3.78B	20.73	4.47%	―	-9.75%	―
Sector *	54 Neutral	$5.28B	3.29	-45.38%	2.80%	16.77%	-0.08%
6185	48 Neutral	HK$10.54B	―	-4.41%	―	94.98%	85.69%
2181	42 Neutral	HK$2.06B	―	-86.56%	―	190.48%	40.11%

Mabpharm Limited Corporate Events

Mabpharm Limited Announces 2025 Annual General Meeting and Share Repurchase Proposal

Mabpharm Limited has announced its upcoming Annual General Meeting (AGM) scheduled for June 18, 2025, in Shanghai. Key agenda items include the consideration of the company’s audited financial statements for 2024, re-election of several directors, re-appointment of Ernst & Young as auditors, and a proposal to authorize the company to repurchase up to 10% of its issued shares. This announcement reflects the company’s ongoing governance and strategic financial management, potentially impacting shareholder value and market confidence.

Mabpharm Limited Reports Significant Revenue Growth Amidst Financial Challenges

Mabpharm Limited reported its financial results for the year ended December 31, 2024, showing a significant increase in revenue by 196.3% to RMB 258,228,000 compared to the previous year. Despite the revenue growth, the company recorded a loss before tax of RMB 127,947,000, which is an improvement from the previous year’s loss. The results reflect increased selling and distribution expenses and a reduction in research and development expenses, impacting the company’s financial performance and market positioning.

Mabpharm Limited Schedules Board Meeting for Annual Results Review

Mabpharm Limited has announced that its board of directors will convene on March 26, 2025, to review and approve the company’s annual financial results for the year ending December 31, 2024. This meeting is significant as it will address the company’s financial performance and any other business matters, potentially impacting its market positioning and stakeholder interests.